A comprehensive view of Injectables / Infusions / IV Drips. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Packaging Industry Market Intelligence Service.
Eli Lilly to acquire FDA-approved manufacturing facility from Nexus Pharmaceuticals to expand its injectable product manufacturing and meet increased demands; production at the Pleasant Prairie, Wisconsin, facility projected to start by end of 2025
Published:
April 22, 2024
by Eli Lilly & Co.
|
FDA approves subcutaneous administration of Takeda’s ENTYVIO (vedolizumab) for maintenance therapy in moderately to severely active Crohn’s Disease
Published:
April 19, 2024
by Business Wire
|
Health Canada approves Merck & Co's KEYTRUDA in combination with chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma treatment following successful Phase 3 trial
Published:
April 19, 2024
by EquityBites
|
High demand for injectable weight-loss drugs has led to supply issues, with most varieties listed in short supply by the FDA; Eli Lilly reports shortages of its Zepbound and Mounjaro could last until 2025
Published:
April 19, 2024
by CBS - 12 WJTV (Jackson, MS)
|
Boston Scientific recalls Obsidio Conformable Embolic blood flow blocking agent due to safety issues; the product is used to block blood supply to tumors and to treat bleeding in patients
Published:
April 18, 2024
by MedTech Dive
|
Ask us about our Packaging Industry market view